Latest filing published 08 May 2026 for 에이프로젠바이오로직스. Read the official filing
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Filings by 김용우 span 3 companies, the busiest being 더존비즈온, 미래에셋증권 and 에이프로젠바이오로직스. Between 19 February 2021 and 8 May 2026, the trades on record add up to 45 filings.
On the open market, the record shows 3 purchases worth €468.0M and 5 sales worth €469.7M. The amount is not disclosed for 4 filings. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2026, the count stands at 3 purchases and 3 sales.
Clusters matter here: 2 out of 3 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
The newest entry dates from 8 May 2026: an open-market sale, in 에이프로젠바이오로직스. The clock since the last published purchase (30 April 2026) now reads 171 days. Typically, a trade is published a median of 7 days after it takes place. The shorter that gap, the sooner other investors can see what insiders have done. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 45 declarations